Portfolio
Our investment focus is exclusively Smart Data and Digital Health. In the past we also invested in diagnostics and therapeutics.
Current investments
-
Real-world patient experience platform for oncology enabling best treatment choices and new therapies
More infoCommercial stage
More info -
In silico clinical trials platform. Uses
More info
simulation to reduce the risk of R&D
decisions by predicting the clinical benefits
of new drugs in virtual clinical trials before
human trials beginCommercial stage
More info -
Digital therapeutics and patient monitoring tools for oncology
More infoCommercial stage
More info -
High performance genomics and clinical big data management platform.
More infoCommercial, with global customer base
More info -
Point of care turn-key Dx platforms.
More info
Instruments and cartridges for simple and rapid molecular diagnosticsIdylla platform and first test launched in September 2014
More info
IPO in April 2015 -
Life-saving detection of sepsis
More info
Host response signature for early identification of sepsisFDA approved test
More info -
Signatures to guide cancer treatment.
More info
Prognostic tests for cancer severity and recurrence.On the market since 2004 (Europe) and 2008 (USA)
More info -
Fusion of Effimune and the Euronext listed OSE Pharma. Immunomodulation in autoimmunity, transplantation, and immuno-oncology
More info2 clinical stage programs, several preclinical programs
More info -
Life science platform helps translate breakthrough science into drugs by providing an incubator and resources for young biotechs
More info4 portfolio companies, three in clinical stage, one IPO. One merger with a public company
More info
Past investments
-
PasNas research platform.
More info
First-in-class drugs for precision treatment of MDR gram-negative infections.Preclinical
More info -
New solutions for MDx pretreatment
Sample preparation technologies for molecular diagnostics
More infoDevelopment phase of magnetic bead handling technology
More info -
Developer of Colox test for blood-based Colorectal Cancer screening
Market entry in Switzerland through collaboration with Novigenix in 2014
-
Focused on active immunotherapy for autoimmune and inflammatory diseases
Initial public offering (IPO) in 2010
More infoCurrent vaccine development efforts are in Crohn’s disease, rheumatoid arthritis and lupus. In Phase IIb/III
More info